 Mario Enrico Canonico
Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peripheral Arterial Disease | 9 | 2026 | 504 | 3.040 |
Why?
| | Platelet Aggregation Inhibitors | 18 | 2026 | 496 | 2.850 |
Why?
| | Acute Coronary Syndrome | 10 | 2026 | 295 | 2.320 |
Why?
| | Percutaneous Coronary Intervention | 12 | 2026 | 547 | 1.860 |
Why?
| | Rivaroxaban | 4 | 2026 | 268 | 1.860 |
Why?
| | Aspirin | 6 | 2026 | 402 | 1.810 |
Why?
| | Factor Xa Inhibitors | 3 | 2026 | 187 | 1.760 |
Why?
| | Fibrinolytic Agents | 6 | 2025 | 290 | 1.710 |
Why?
| | Heart Failure | 10 | 2026 | 2324 | 1.560 |
Why?
| | Lower Extremity | 5 | 2026 | 440 | 1.270 |
Why?
| | Stroke Volume | 8 | 2026 | 650 | 1.190 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2025 | 68 | 1.060 |
Why?
| | ST Elevation Myocardial Infarction | 3 | 2026 | 64 | 1.030 |
Why?
| | Vascular Surgical Procedures | 2 | 2026 | 343 | 0.900 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2025 | 299 | 0.700 |
Why?
| | Thrombosis | 2 | 2024 | 396 | 0.690 |
Why?
| | Anticholesteremic Agents | 1 | 2023 | 154 | 0.680 |
Why?
| | Hyperglycemia | 1 | 2025 | 374 | 0.680 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2026 | 2573 | 0.680 |
Why?
| | Endovascular Procedures | 1 | 2026 | 385 | 0.660 |
Why?
| | Purinergic P2Y Receptor Antagonists | 8 | 2026 | 71 | 0.660 |
Why?
| | Hypertension | 6 | 2026 | 1262 | 0.650 |
Why?
| | Adenosine Monophosphate | 4 | 2026 | 86 | 0.640 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 657 | 0.610 |
Why?
| | Venous Thrombosis | 1 | 2022 | 193 | 0.600 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.600 |
Why?
| | Blood Platelets | 3 | 2024 | 379 | 0.600 |
Why?
| | Mobile Applications | 1 | 2022 | 197 | 0.590 |
Why?
| | Hypoglycemic Agents | 3 | 2026 | 1388 | 0.590 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 438 | 0.580 |
Why?
| | Sex Characteristics | 2 | 2025 | 776 | 0.550 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 387 | 0.550 |
Why?
| | Coronavirus Infections | 2 | 2020 | 381 | 0.550 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 326 | 0.520 |
Why?
| | Precision Medicine | 1 | 2021 | 454 | 0.490 |
Why?
| | Humans | 52 | 2026 | 144667 | 0.490 |
Why?
| | Hemorrhage | 4 | 2026 | 813 | 0.490 |
Why?
| | Drug Therapy, Combination | 5 | 2026 | 1044 | 0.470 |
Why?
| | Platelet Aggregation | 4 | 2026 | 98 | 0.460 |
Why?
| | Blood Glucose | 1 | 2025 | 2326 | 0.440 |
Why?
| | Neoplasms | 4 | 2024 | 2873 | 0.420 |
Why?
| | International Classification of Diseases | 2 | 2025 | 147 | 0.410 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1076 | 0.400 |
Why?
| | Ventricular Function, Left | 5 | 2026 | 536 | 0.400 |
Why?
| | Treatment Outcome | 14 | 2026 | 11735 | 0.400 |
Why?
| | Pragmatic Clinical Trials as Topic | 2 | 2025 | 133 | 0.390 |
Why?
| | Coronary Artery Disease | 4 | 2025 | 743 | 0.380 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2026 | 1742 | 0.380 |
Why?
| | Aged | 17 | 2026 | 25955 | 0.370 |
Why?
| | Pandemics | 2 | 2020 | 1700 | 0.360 |
Why?
| | Multicenter Studies as Topic | 2 | 2025 | 408 | 0.360 |
Why?
| | Postoperative Complications | 1 | 2024 | 2950 | 0.350 |
Why?
| | Aged, 80 and over | 6 | 2026 | 8284 | 0.340 |
Why?
| | Middle Aged | 16 | 2026 | 35971 | 0.330 |
Why?
| | Antihypertensive Agents | 2 | 2026 | 512 | 0.330 |
Why?
| | Double-Blind Method | 2 | 2026 | 2033 | 0.310 |
Why?
| | Blood Pressure | 4 | 2026 | 1766 | 0.310 |
Why?
| | Male | 23 | 2026 | 72431 | 0.300 |
Why?
| | Anticoagulants | 4 | 2022 | 729 | 0.290 |
Why?
| | Prevalence | 4 | 2025 | 2839 | 0.290 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2026 | 109 | 0.270 |
Why?
| | Female | 19 | 2026 | 78304 | 0.260 |
Why?
| | Betacoronavirus | 2 | 2020 | 286 | 0.260 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 392 | 0.260 |
Why?
| | Incretins | 1 | 2026 | 21 | 0.240 |
Why?
| | Aminobutyrates | 1 | 2026 | 31 | 0.230 |
Why?
| | Tetrazoles | 1 | 2026 | 49 | 0.230 |
Why?
| | Chagas Cardiomyopathy | 1 | 2026 | 27 | 0.230 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2026 | 41 | 0.230 |
Why?
| | Risk Factors | 6 | 2026 | 10796 | 0.230 |
Why?
| | Limb Salvage | 1 | 2026 | 73 | 0.230 |
Why?
| | Bumetanide | 1 | 2025 | 5 | 0.230 |
Why?
| | Adenosine | 2 | 2024 | 255 | 0.220 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2025 | 17 | 0.220 |
Why?
| | Diuretics | 1 | 2025 | 68 | 0.220 |
Why?
| | Atrial Fibrillation | 2 | 2021 | 555 | 0.220 |
Why?
| | Glucagon-Like Peptides | 1 | 2026 | 70 | 0.210 |
Why?
| | Peptide Fragments | 2 | 2026 | 691 | 0.210 |
Why?
| | Coronary Angiography | 4 | 2021 | 324 | 0.210 |
Why?
| | Hospitalization | 2 | 2025 | 2446 | 0.210 |
Why?
| | Morphine Derivatives | 1 | 2023 | 19 | 0.200 |
Why?
| | Tablets | 1 | 2023 | 41 | 0.200 |
Why?
| | Ventricular Remodeling | 1 | 2026 | 275 | 0.200 |
Why?
| | Subtilisin | 1 | 2023 | 4 | 0.200 |
Why?
| | Secondary Prevention | 1 | 2025 | 255 | 0.200 |
Why?
| | Cardiology | 2 | 2025 | 359 | 0.200 |
Why?
| | Proprotein Convertases | 1 | 2023 | 16 | 0.200 |
Why?
| | Recombinant Fusion Proteins | 1 | 2026 | 667 | 0.190 |
Why?
| | Proprotein Convertase 9 | 1 | 2023 | 87 | 0.190 |
Why?
| | Comorbidity | 2 | 2025 | 1652 | 0.190 |
Why?
| | Atrial Remodeling | 1 | 2022 | 10 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 116 | 0.180 |
Why?
| | Echocardiography | 5 | 2024 | 644 | 0.170 |
Why?
| | Bundle-Branch Block | 1 | 2021 | 36 | 0.170 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2021 | 34 | 0.170 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 359 | 0.170 |
Why?
| | Cardiotoxicity | 1 | 2021 | 34 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2025 | 409 | 0.170 |
Why?
| | Frailty | 1 | 2024 | 200 | 0.170 |
Why?
| | Drug Compounding | 1 | 2021 | 107 | 0.160 |
Why?
| | Coronary Stenosis | 1 | 2020 | 38 | 0.160 |
Why?
| | Coronary Occlusion | 1 | 2020 | 20 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2025 | 607 | 0.160 |
Why?
| | Radial Artery | 2 | 2021 | 72 | 0.160 |
Why?
| | Drug-Eluting Stents | 1 | 2020 | 88 | 0.160 |
Why?
| | Myocarditis | 1 | 2021 | 101 | 0.160 |
Why?
| | Smoking Cessation | 1 | 2024 | 436 | 0.160 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2021 | 155 | 0.160 |
Why?
| | Shock, Cardiogenic | 1 | 2020 | 64 | 0.160 |
Why?
| | Angioplasty, Balloon | 1 | 2021 | 93 | 0.150 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2023 | 337 | 0.150 |
Why?
| | Italy | 3 | 2025 | 114 | 0.140 |
Why?
| | Chronic Disease | 1 | 2025 | 1810 | 0.140 |
Why?
| | Heart Arrest | 1 | 2023 | 406 | 0.140 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5870 | 0.140 |
Why?
| | Hepatitis C, Chronic | 1 | 2020 | 152 | 0.140 |
Why?
| | United States | 3 | 2025 | 16018 | 0.140 |
Why?
| | Pulmonary Embolism | 1 | 2020 | 241 | 0.140 |
Why?
| | Students, Medical | 1 | 2023 | 374 | 0.140 |
Why?
| | Time Factors | 2 | 2026 | 7140 | 0.130 |
Why?
| | Cardiomyopathies | 1 | 2021 | 334 | 0.130 |
Why?
| | Registries | 5 | 2026 | 2392 | 0.130 |
Why?
| | Biomarkers | 2 | 2025 | 4261 | 0.120 |
Why?
| | Retrospective Studies | 6 | 2025 | 17149 | 0.120 |
Why?
| | Telemedicine | 1 | 2025 | 957 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2023 | 1505 | 0.120 |
Why?
| | Colorado | 1 | 2025 | 4558 | 0.110 |
Why?
| | Femoral Artery | 1 | 2016 | 190 | 0.110 |
Why?
| | Heart Ventricles | 1 | 2020 | 751 | 0.110 |
Why?
| | Cross-Over Studies | 2 | 2025 | 605 | 0.090 |
Why?
| | Obesity | 1 | 2026 | 3070 | 0.090 |
Why?
| | Cardiac Catheterization | 1 | 2016 | 557 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2201 | 0.090 |
Why?
| | Administration, Oral | 2 | 2021 | 851 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2020 | 2172 | 0.070 |
Why?
| | Prospective Studies | 3 | 2026 | 7994 | 0.070 |
Why?
| | Prognosis | 3 | 2021 | 4312 | 0.070 |
Why?
| | Valsartan | 1 | 2026 | 32 | 0.060 |
Why?
| | Biphenyl Compounds | 1 | 2026 | 66 | 0.060 |
Why?
| | Naphthyridines | 1 | 2025 | 20 | 0.060 |
Why?
| | Nasal Sprays | 1 | 2025 | 6 | 0.060 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2026 | 115 | 0.060 |
Why?
| | Spironolactone | 1 | 2025 | 39 | 0.060 |
Why?
| | Administration, Intranasal | 1 | 2025 | 93 | 0.060 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2024 | 6 | 0.050 |
Why?
| | Biological Availability | 1 | 2025 | 143 | 0.050 |
Why?
| | Platelet Function Tests | 1 | 2024 | 35 | 0.050 |
Why?
| | Drug Combinations | 1 | 2026 | 393 | 0.050 |
Why?
| | Hypolipidemic Agents | 1 | 2025 | 89 | 0.050 |
Why?
| | Adult | 3 | 2022 | 40489 | 0.050 |
Why?
| | Risk Assessment | 2 | 2025 | 3729 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2024 | 779 | 0.050 |
Why?
| | Prasugrel Hydrochloride | 1 | 2022 | 22 | 0.040 |
Why?
| | Equivalence Trials as Topic | 1 | 2022 | 36 | 0.040 |
Why?
| | Emergencies | 1 | 2023 | 175 | 0.040 |
Why?
| | Gadolinium | 1 | 2021 | 84 | 0.040 |
Why?
| | Vitamin K | 1 | 2021 | 45 | 0.040 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2021 | 70 | 0.040 |
Why?
| | Heart Atria | 1 | 2022 | 141 | 0.040 |
Why?
| | Exercise Therapy | 1 | 2025 | 475 | 0.040 |
Why?
| | Disease Management | 1 | 2024 | 650 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2104 | 0.040 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2020 | 122 | 0.040 |
Why?
| | Hepacivirus | 1 | 2020 | 243 | 0.040 |
Why?
| | Coronary Vessels | 1 | 2020 | 246 | 0.040 |
Why?
| | Contrast Media | 1 | 2021 | 492 | 0.030 |
Why?
| | Acute Disease | 1 | 2021 | 1029 | 0.030 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2020 | 248 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3329 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 2019 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2117 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2114 | 0.030 |
Why?
| | Stents | 1 | 2020 | 557 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2922 | 0.020 |
Why?
| | Incidence | 1 | 2020 | 2892 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 638 | 0.020 |
Why?
| | Body Mass Index | 1 | 2022 | 2419 | 0.020 |
Why?
| | Quality of Life | 1 | 2025 | 3183 | 0.020 |
Why?
| | Patient Safety | 1 | 2016 | 353 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5957 | 0.020 |
Why?
| | Length of Stay | 1 | 2016 | 1339 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1948 | 0.020 |
Why?
| | Animals | 1 | 2021 | 37948 | 0.010 |
Why?
|
|
Canonico's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|